Latest Clinical Lymphoma & Myeloma Stories
CALGARY, May 10 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S.
NEW YORK, April 12, 2011 /PRNewswire-USNewswire/ -- The Bone and Cancer Foundation (BCF) provides information for cancer patients who have bone related complications including metastasis and cancer treatment induced bone loss.
Results with Estybon (ON 01910.Na) in Patients with myelodysplastic syndromes; ON 013105 cyclin D1 inhibitor active in models of mantle cell lymphoma.
NEW YORK, Dec. 1, 2010 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the launch of their revolutionary molecular test for individuals diagnosed with multiple myeloma, MyPRS(TM).
WHITE PLAINS, N.Y., Dec. 1, 2010 /PRNewswire/ -- Researchers from around the world will present their findings in blood cancer research at the annual American Society of Hematology (ASH) conference in Orlando December 4-7, 2010.
NEW YORK, Oct. 26 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the formation of their Scientific Advisory Board.
- The governor of a province or people.